Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.

@article{Fenton2012ResistanceTE,
  title={Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.},
  author={Tim R. Fenton and David Nathanson and Claudio Ponte de Albuquerque and Daisuke Kuga and Akio Iwanami and Julie Dang and Huijun Yang and Kazuhiro Tanaka and Sueli Mieko Oba-Shinjo and Miyuki Uno and Mar{\'i}a del Mar Inda and Jill Wykosky and Robert M. Bachoo and C. David James and Ronald A. Depinho and Scott R. Vandenberg and Huilin Zhou and Suely Kazue Nagahashi Marie and Paul Mischel and Webster K Cavenee and Frank B Furnari},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2012},
  volume={109 35},
  pages={14164-9}
}
Glioblastoma multiforme (GBM) is the most aggressive of the astrocytic malignancies and the most common intracranial tumor in adults. Although the epidermal growth factor receptor (EGFR) is overexpressed and/or mutated in at least 50% of GBM cases and is required for tumor maintenance in animal models, EGFR inhibitors have thus far failed to deliver significant responses in GBM patients. One inherent resistance mechanism in GBM is the coactivation of multiple receptor tyrosine kinases, which… CONTINUE READING